+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Open-Angle Glaucoma - Epidemiology Forecast to 2030

  • ID: 4855537
  • Report
  • April 2020
  • Region: Global
  • 100 pages
  • DelveInsight
1 of 2
Open-angle glaucoma (OAG)-Epidemiology Forecast - 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of OAG in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

Open-angle glaucoma (OAG) - Disease Understanding

Open-angle glaucoma (OAG) is a progressive form of glaucoma in which the channel formed between the iris and the cornea remains open and tissue changes along the channel, which gradually reduces the drainage of the aqueous humor through the trabecular meshwork of the eye's anterior chamber. It is the most common form of glaucoma which accounts for the majority of the glaucoma cases. The term “Open-Angle” refers to the angle where the iris meets the cornea and is as wide and open as it should be. OAG is mainly caused by the slow clogging of the drainage canals, resulting in increased eye pressure.

The OAG is primarily divided into two subtypes, i.e., Primary OAG and Secondary OAG. The risk factors of open-angle glaucoma are divided into four categories, general factors, ocular factors, nonocular factors, and ocular hypertension.

Open-angle glaucoma (OAG) - Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Glaucoma in the 7MM, Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM, Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM, Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM and Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM scenario of OAG in the 7MM countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

As per the analysis, a higher percentage of diagnosed prevalence of OAG was observed for females, in comparison to males, in all the 7MM countries. The research analysts have assessed that the total prevalent population of Glaucoma in the 7MM was 9,819,080 in 2017. In addition to this it was also assessed that among those with glaucoma in the 7MM, more than 8.5 million were diagnosed with OAG. The estimate suggests that the United States witnessed the highest number of cases with OAG, as compared to other 7MM countries. As per The estimates, the country accounted for approximately 2,749,378 cases in 2017.

Among the EU-5 countries, Germany accounted for the highest number of glaucoma cases in 2017, which was observed to be equivalent to more than 25% of the total affected population in this region. The number of cases for glaucoma was observed to be 1,041,889 in the country for 2017. However, Spain accounted for the lowest number of glaucoma cases in 2017, which was approximately 13.33% of the total affected population of EU-5 countries. According to the publisher's analysts, Japan accounted for the second-highest number of OAG patients, i.e., 28.79% of the total OAG population in the 7MM countries.

According to the publisher's assessment, it has been observed that OAG prevalence varied across the 7MM countries, based on the age-specific prevalence of the disease. For instance, the highest proportion was observed in the 70-79 years age group in the US, while in the EU-5 countries, people aged ≥80 years accounted for the maximum patient pool. In contrast, the middle age population aged 50-59 years contributed to the highest patient pool in Japan.

Report Scope
  • The report covers a detailed overview of Open-angle glaucoma explaining its causes, symptoms, classification, pathophysiology, and diagnosis.
  • The report provides insight into the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Open-angle glaucoma
  • The report helps to recognize the growth opportunities in the 7MM countries with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by total Prevalence of Glaucoma in the 7MM, Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM, Gender-Specific Diagnosed Prevalence in the 7MM, Age-Specific Diagnosed Prevalence in the 7MM, and Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM.
Open-angle glaucoma Report Key Strengths
  • 11 Year Forecast
  • 7MM Coverage
  • Total Prevalence of Glaucoma
  • Total Diagnosed Prevalent Population of Open-Angle Glaucoma
  • Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma
  • Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma
  • Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma
Open-angle glaucoma Report Assessment
  • Patient segmentation
  • Disease risk and burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Executive Summary of Open-Angle Glaucoma

3. Open-Angle Glaucoma (OAG): Epidemiology Overview at a Glance
3.1. Total Prevalent Cases of OAG in 2017
3.2. Total Prevalent Cases of OAG in 2030

4. Open-Angle Glaucoma: Disease Background and Overview
4.1. Introduction
4.2. Classification of Open-Angle Glaucoma
4.3. Signs and Symptoms of Open-Angle Glaucoma
4.4. Risk Factors of Primary Open-Angle Glaucoma (POAG)
4.4.1. General
4.4.2. Ocular
4.4.3. Nonocular
4.4.4. Ocular Hypertension
4.5. Pathophysiology of Primary Open-Angle Glaucoma (POAG)
4.6. Genes Involved in Primary Open-Angle Glaucoma
4.6.1. Myocilin
4.6.2. Optineurin
4.6.3. TANK-binding Kinase-1 (TBK1)
4.6.4. WD-repeat domain 36 (WDR36, OMIM 609669)
4.7. Biomarkers associated with Primary Open Angle Glaucoma (POAG)
4.8. Diagnosis of Open-Angle Glaucoma
4.8.1. Diagnosis of Primary Open-Angle Glaucoma
4.8.2. Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines

5. Case Reports
5.1. Managing Juvenile Open-Angle Glaucoma
5.2. Visual improvement following glaucoma surgery: a case report
5.3. Evidence-based medicine in glaucoma surgery

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Epidemiology Methodology
6.3. Total Prevalence of Glaucoma in the 7MM
6.4. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM
6.5. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM

7. United States Epidemiology
7.1. Assumptions and Rationale
7.2. Total Prevalence of Glaucoma in the United States
7.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United States
7.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States
7.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States
7.6. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States

8. EU5 Epidemiology
8.1. Germany Epidemiology
8.1.1. Assumptions and Rationale
8.1.2. Total Prevalence of Glaucoma in Germany
8.1.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Germany
8.1.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
8.1.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
8.1.6. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
8.2. France Epidemiology
8.2.1. Assumptions and rationale
8.2.2. Total Prevalence of Glaucoma in France
8.2.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in France
8.2.4. Gender-specific Diagnosed Prevalence of Open-Angle Glaucoma in France
8.2.5. Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in France
8.2.6. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France
8.3. Italy Epidemiology
8.3.1. Assumptions and Rationale
8.3.2. Total Prevalence of Glaucoma in Italy
8.3.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Italy
8.3.4. Gender-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
8.3.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
8.3.6. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
8.4. Spain Epidemiology
8.4.1. Assumptions and Rationale
8.4.2. Total Prevalence of Glaucoma in Spain
8.4.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Spain
8.4.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
8.4.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
8.4.6. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
8.5. United Kingdom Epidemiology
8.5.1. Assumptions and Rationale
8.5.2. Total Prevalence of Glaucoma in the United Kingdom
8.5.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United Kingdom
8.5.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom
8.5.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom
8.5.6. Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom

9. Japan Epidemiology
9.1. Assumptions and Rationale
9.2. Total Prevalence of Glaucoma in Japan
9.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Japan
9.4. Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan
9.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan
9.6. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan

10. Appendix
10.1. Report Methodology

11. Capabilities

12. Disclaimer

13. About the Publisher
Note: Product cover images may vary from those shown
Adroll
adroll